Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Interest & Investment Income: 2021-2022

Historic Interest & Investment Income for Kiniksa Pharmaceuticals International (KNSA) over the last 2 years, with Sep 2022 value amounting to $322,000.

  • Kiniksa Pharmaceuticals International's Interest & Investment Income rose 6340.00% to $322,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $536,000, marking a year-over-year change of. This contributed to the annual value of $97,000 for FY2021, which is 91.45% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Interest & Investment Income of $322,000 as of Q3 2022, which was up 212.62% from $103,000 recorded in Q2 2022.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Interest & Investment Income registered a high of $322,000 during Q3 2022, and its lowest value of $5,000 during Q3 2021.
  • Over the past 2 years, Kiniksa Pharmaceuticals International's median Interest & Investment Income value was $34,000 (recorded in 2022), while the average stood at $79,429.
  • Data for Kiniksa Pharmaceuticals International's Interest & Investment Income shows a peak YoY soared of 6,340.00% (in 2022) over the last 5 years.
  • Kiniksa Pharmaceuticals International's Interest & Investment Income (Quarterly) stood at $77,000 in 2021, then soared by 6,340.00% to $322,000 in 2022.
  • Its Interest & Investment Income was $322,000 in Q3 2022, compared to $103,000 in Q2 2022 and $34,000 in Q1 2022.